Metformin

6-month clinical glycemic control rate

Beta cell function

Change in HbA1c from baseline to Week 24.

Ovulation rate

Metabolic late effects

Success Rate of Treatment Regimens in Restoring Menstrual Regularity and/or Achieving Pregnancy

Mean morphometric diffusion capacity for oxygen (MMDC) in placental tissues

Leukocyte telomerase length

Duration of menstruation (day)

recruitment rate

flow-mediated dilation

Weight (wt) in Pounds (Lbs)..

GLP-1 response as incremental area under curve (iAUC)

Mean Blood Glucose Concentration After First Day of Treatment

Combined end-point of non-detectable serum HCV-RNA (<100 copies/mL) and

Proportion of Participants Achieving PASI75 at Week 24

To investigate whether four months of Metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic sperm injection) will increase clinical pregnancy rate in normal weight PCOS-women

Individual's percentage change in body weight

Live-birth rate

Evaluate lesion size in millimeters

Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire

Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent

Increase in Number of Expressed Genes in Muscle and Adipose Tissue Using RNA Sequencing (RNA-Seq)

Study Endpoints Will Include Measurements of Insulin Sensitivity, Hepatic Insulin Clearance, and Altered Parameters of Lipid Metabolism, Changes in the Histological Features That Define NAFLD, and Quantitative Measurements of Visceral and Peripheral Fat.

Change From Baseline in A1C at Week 26: Excluding Rescue Approach

Change from baseline in HbA1c

Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue

Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Percentage of Participants With at Least One Symptomatic Hypoglycemic Event

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

percentage of HbA1c change from baseline

Change From Baseline in HbA1c (Hemoglobin A1C) at Week24

HOMA-IR reduction

Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12

28 days mortality

Effect of empagliflozin plus linagliptin vs metformin plus insulin glargine on basal NO activity of renal vasculature (response of RPF (renal plasma flow) to L-NMMA (NG-monomethyl-L-arginine) infusion)

Change in BMI from baseline

Clinical Outcomes

Change in Body Mass Index Z-score

Glucose Metabolism

Hematologic response (erythroid)

Improvement in Left Ventricular Ejection Fraction

Radiographic bone fill assessed in percentage

Bone defect fill

Decrease of at least 5% of body weight and the reduction in the body mass index.

Disease progression-free survival (PFS)

Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus

Change From Baseline in Derived Plasma Glucose Parameter Over a 24-hour Period-fasting and Weighted Mean Glucose Area Under Curve (AUC[0-24 Hour])

- Clinical assessment of disease activity

Measure Metformin Induced effects in phosphorylation of S6K, 4E-BP-1 and AMPK via immunohistochemical analysis

Change in BK channel gene expression

Pathological Complete Response (pCR) rate

bioequivalence will be demonstrated if the 90% confidence interval (CI) for the formulation effect is contained within the interval of 0.8000-1.2500 for AUC(0-t), AUCinf and Cmax with respect to both dapagliflozin and metformin.

Regulation of Menstrual Cycle

metformin, rosuvastatin Cmax

Bioequivalence on Cmax, AUC, Tmax,t1/2 parameters

Pharmacokinetic variable - Cmax

Bioequivalence

Part A: Maximum Observed Plasma Concentration (Cmax) for Bupropion

Renal clearance of Metformin based on genotypes

Pharmacokinetic variable - AUCt

Maximum observed plasma concentration (Cmax) in plasma for metformin with and without BMS-986165

Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)

Cmax

Area under the concentration versus time curve (AUC) of metformin from dosing time (0) to tau (dosing interval) (AUCtau) after 3.5 days.

For Empagliflozin & Linagliptin & Metformin; Maximum concentration obtained (Cmax)

Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine

The maximum tolerated dose of metformin in combination with a fixed dose of 150 mg erlotinib daily

Change in Insulin Resistance Between Different Exercise Modes in Obese Patients